Fluoguide A/s · OMXSTO:FLUO
Fluoguide A/s — Investor Presentation (January 2026)
11 slides from Fluoguide A/s's investor presentation, Jan 21, 2026
Slide 1: Light up cancer, maximize surgical outcome
Light up cancer maximize surgical outcome 2026 Morten Albrechtsen, CEO
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements that provide FluoGuide’s expectations or forecasts of future events such as new product developments, regulatory approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and may be impact
Slide 3: Fighting Cancer - a huge and growing need for precision surgery
Fighting Cancer - a huge and growing need for precision surgery ≈20 million Surgery is the primary new patients treatment are diagnosed with Radiation- and chemotherapies cancer every year are the two other main options ≈ 90% ≈12 million ≈ 40% ≈50% of the patients cancer patients experience local re
Slide 4: Unique uPAR-targeted image agent with strong clinical data in multiple indications
Unique uPAR-targeted image agent with strong clinical data in multiple indications High Grade Glioma (Trial # CT-001) Normal image as Near-infrared (NIR) the surgeon sees imaging revealed it when checking additional cancer for cancer tissue. left in cavity. Oral head and neck cancer (Trial # CT-003)
Slide 5: Pipeline with low risk and long-term patent protection
Pipeline with low risk and long-term patent protection INDICATION PRE-CLINICAL PHASE I PHASE II PHASE III NEXT FG001 • Initiation of US PII Brain cancer (FGS) registration (CT-006) High-grade glioma • Result of IIT (LGG) Head and Neck cancer (FGS) • PII result (CT-005) Squamous cell carcinoma Photos
Slide 6: Large commercial potential for scaling sales of FG001
Large commercial potential for scaling sales of FG001 Pricing and reimbursement Fluorescent guided surgery: 4-5.000 USD per dose Photosensitizer therapy: 25.000 USD per dose Total procedures: 45 million per year Business Model FG001: Recurrent revenue from sales of drug x70 Surgical system: Revenue
Slide 7: Well-positioned in fluorescence-guided surgery
Well-positioned in fluorescence-guided surgery Compatible Brain Brain Head & Gastro- Breast Lung Colorectal Prostate Bladder Pancreatic Melanoma Ovarian Sarcoma with existing (HGG) (other) Neck intestinal systems P II P II P II P II √ Approved (P II) - Approved - Approved Approved (√) P II Approved
Slide 8: Orphan Drug Designation in high grade glioma and positive FDA feedback
Orphan Drug Designation in high grade glioma and positive FDA feedback • FluoGuide received positive FDA feedback on FG001 in high-grade glioma • Supports both the IND submission and future NDA filing • De-risks the overall regulatory process toward NDA submission • Orphan drug designation has been
Slide 9: Strategic partnerships with leading MedTechs – Expanding reach and adoption
Strategic partnerships with leading MedTechs – Expanding reach and adoption FG001 works with all surgical equipment Non-exclusive partnerships All benefits from partnerships Patients and society: Microscope Intuitive Surgical (robot-assisted surgery) • Provided better surgery to more people Partners
Slide 10: 2026 catalysts: Phase II-data and initiation of registration trial in HGG
2026 catalysts: Phase II-data and initiation of registration trial in HGG 2026 Q1 Q2 Q3 Q4 • Submit Investigational New Drug • First patient enrolled in US phase II (IND) application for US clinical trial registrational trial for HGG (CT-006) (CT-006) Brain • Initiate enrolment of the remaining 10 p
Slide 11: FluoGuide lights up cancer – maximize surgical outcome Q&A
FluoGuide lights up cancer – maximize surgical outcome Q&A Morten Albrechtsen, CEO +45 24 25 62 66 ma@fluoguide.com www.fluoguide.com Follow FluoGuide on LinkedIn: https://www.linkedin.com/company/fluoguide/ Sign up to receive FluoGuide news: https://fluoguide.com/investor/email-alerts/ 11